The detrimental role of galectin‐3 and endoplasmic reticulum stress in the cardiac consequences of myocardial ischemia in the context of obesity

Abstract

AbstractThe association between cardiac fibrosis and galectin‐3 was evaluated in patients with acute myocardial infarction (MI). The role of galectin‐3 and its association with endoplasmic reticulum (ER) stress activation in the progression of cardiovascular fibrosis was also evaluated in obese‐infarcted rats. The inhibitor of galectin‐3 activity, modified citrus pectin (MCP; 100 mg/kg/day), and the inhibitor of the ER stress activation, 4‐phenylbutyric acid (4‐PBA; 500 mg/kg/day), were administered for 4 weeks after MI in obese rats. Overweight‐obese patients who suffered a first MI showed higher circulating galectin‐3 levels, higher extracellular volume, and LV infarcted size, as well as lower E/e'ratio and LVEF compared with normal‐weight patients. A correlation was observed between galectin‐3 levels and extracellular volume. Obese‐infarcted animals presented cardiac hypertrophy and reduction in LVEF, and E/A ratio as compared with control animals. They also showed an increase in galectin‐3 gene expression, as well as cardiac fibrosis and reduced autophagic flux. These alterations were associated with ER stress activation characterized by enhanced cardiac levels of binding immunoglobulin protein, which were correlated with those of galectin‐3. Both MCP and 4‐PBA not only reduced cardiac fibrosis, oxidative stress, galectin‐3 levels, and ER stress activation, but also prevented cardiac functional alterations and ameliorated autophagic flux. These results show the relevant role of galectin‐3 in the development of diffuse fibrosis associated with MI in the context of obesity in both the animal model and patients. Galectin‐3 in tandem with ER stress activation could modulate different downstream mechanisms, including inflammation, oxidative stress, and autophagy.